Harpoon Therapeutics Adds Holger Wesche, Georgia Erbez to C-Suite

Harpoon Therapeutics has promoted Holger Wesche to chief scientific officer. Wesche had been senior vice president, research, of the South San Francisco, CA-based cancer immunotherapy developer. Harpoon also named Georgia Erbez its chief financial officer. Erbez was most recently chief business officer and CFO of Zosano Pharma (NASDAQ: [[ticker:ZSAN]]). The executive moves follow Harpoon’s appointment of Natalie Sacks to the chief medical officer post earlier this month. Harpoon’s lead drug, HPN424, is in early-stage clinical testing as a treatment for prostate cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan